| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | -0.0056 | 0.9 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | -0.0063 | 0.9 |
| mRNA | ISOX:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | 0.0052 | 0.9 |
| mRNA | MG-132 | CTRPv2 | pan-cancer | AAC | 0.0092 | 0.9 |
| mRNA | Axitinib | CTRPv2 | pan-cancer | AAC | -0.0052 | 0.9 |
| mRNA | BRD-K11533227 | CTRPv2 | pan-cancer | AAC | -0.0057 | 0.9 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | 0.0057 | 0.9 |
| mRNA | BRD-K85133207 | CTRPv2 | pan-cancer | AAC | 0.0056 | 0.9 |
| mRNA | YL54 | CTRPv2 | pan-cancer | AAC | -0.0058 | 0.9 |